Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646328 | 0.82 | FAAH (0.50) | FAAHCYP1A2CYP2D6HDAC1TRPV1 | |
| SCHEMBL782996 | 0.80 | CYP1A2 (0.51) | FAAHCYP1A2CYP2D6HDAC1TRPV1 | |
| SCHEMBL10499852 | 0.79 | CYP1A2 (0.54) | FAAHCYP1A2CYP2D6HDAC1HSD17B10 | |
| SCHEMBL15073551 | 0.72 | RPS6KB1 (0.50) | FAAHCYP1A2CYP2D6HDAC1HSD17B10 | |
| SCHEMBL20224882 | 0.72 | CYP1A2 (0.52) | FAAHCYP1A2CYP2D6HDAC1HSD17B10 | |
| SCHEMBL28045022 | 0.71 | KDM4E (0.53) | KMT2A | |
| SCHEMBL17188052 | 0.70 | HTR2A (0.50) | CYP1A2CYP2D6HDAC1HSD17B10POLB | |
| SCHEMBL15055228 | 0.70 | RPS6KB1 (0.48) | FAAHCYP1A2CYP2D6HDAC1HSD17B10 | |
| SCHEMBL3913062 | 0.70 | DRD2 (0.41) | LMNAKMT2AALDH1A1 | |
| SCHEMBL22110225 | 0.69 | FAAH (0.50) | FAAHCYP1A2HSD17B10TRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| EP-2794571-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096194-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | FAAH 684/4885CYP1A2 2527/4885CYP2D6 3304/4885 |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MAP3K15, MAP3K12, MAP3K11 | FAAH 1182/4885CYP1A2 2178/4885CYP2D6 3122/4885 |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | FAAH 828/4885CYP1A2 2894/4885CYP2D6 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.